Subcutaneous Mosunetuzumab Approved for Relapsed Follicular Lymphoma

The treatment landscape for relapsed or refractory (R/R) follicular lymphoma has become a little more streamlined with the recent approval of a subcutaneous (sub-Q) formulation of mosunetuzumab. This development, highlighted by pharmacy expert Zahra Mahmoudjafari, PharmD, MBA, BCOP, promises to improve practice efficiency for patients facing this challenging blood cancer. Follicular lymphoma, a gradual-growing type of non-Hodgkin lymphoma, often returns after initial treatment, necessitating further interventions.

Mosunetuzumab is a bispecific antibody, meaning it’s engineered to target two different proteins simultaneously. In this case, it targets the CD20 protein found on lymphoma cells and the CD3 protein found on immune T cells. By bringing these two together, mosunetuzumab essentially directs the patient’s own immune system to attack and destroy the cancerous cells. Previously administered intravenously, the shift to a sub-Q formulation simplifies administration for both patients and healthcare providers.

Long-Term Efficacy and the Shift to Subcutaneous Delivery

Recent data, including a 3-year follow-up study published in Blood, demonstrates the sustained efficacy of mosunetuzumab in patients with R/R follicular lymphoma who have already undergone multiple lines of therapy. The study followed 90 patients and showed encouraging long-term outcomes. The move to a subcutaneous formulation isn’t just about convenience; an economic analysis presented at a recent conference suggests that sub-Q mosunetuzumab offers better practice efficiency compared to another treatment option, epcoritamab, in the third-line or later setting. This analysis, led by Z. Mahmoudjafari, K. L. Rosettie, and M. Wu, points to potential cost savings and reduced administrative burden.

The intravenous administration of cancer therapies often requires patients to spend significant time at infusion centers. Subcutaneous injections, which can be administered in a clinic or potentially even at home with appropriate support, reduce this burden. This is particularly important for patients who live far from specialized cancer centers or who have difficulty with travel.

Who Benefits from Mosunetuzumab?

Mosunetuzumab is specifically indicated for adult patients with R/R follicular lymphoma who have received at least two prior lines of systemic therapy. This means it’s generally used when other treatments have stopped working or have become ineffective. Follicular lymphoma is a relatively common type of non-Hodgkin lymphoma, accounting for approximately 20-30% of all cases. The National Cancer Institute estimates that about 85,000 modern cases of non-Hodgkin lymphoma will be diagnosed in the United States in 2024. Although this figure encompasses all subtypes, follicular lymphoma represents a significant portion of these diagnoses.

Understanding the Evidence: Trial Design and Limitations

The pivotal Phase 1/2 study informing the approval of mosunetuzumab employed a fixed-duration treatment schedule. This means patients received the drug for a pre-defined period, rather than continuing until the disease progressed. Fixed-duration therapies are increasingly favored in lymphoma treatment as they can minimize long-term exposure to potentially toxic drugs. However, it’s important to note that the study population was heavily pre-treated, with patients having received a median of three prior lines of therapy. This means the results may not be directly generalizable to patients with less advanced disease or those who have not yet received extensive treatment. The study’s sample size (90 patients) is relatively small, which limits the statistical power to detect less common side effects or subtle differences in efficacy.

Mosunetuzumab in Combination: Exploring New Avenues

Researchers are similarly investigating the potential of combining mosunetuzumab with other therapies to further improve outcomes in R/R follicular lymphoma. A Phase 2 clinical trial (NCT06492837) is currently underway, evaluating the efficacy and safety of mosunetuzumab in combination with zanubrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor. BTK inhibitors block a key signaling pathway involved in the growth and survival of lymphoma cells. The rationale behind this combination is that mosunetuzumab activates the immune system to kill cancer cells, while zanubrutinib directly targets the cancer cells themselves, potentially leading to a synergistic effect.

What are Bispecific Antibodies?

Bispecific antibodies represent a relatively new class of immunotherapy. Traditional antibodies bind to a single target. Bispecific antibodies, however, are engineered to bind to two different targets simultaneously. This unique ability allows them to bridge the gap between cancer cells and immune cells, enhancing the immune response against the tumor. Other bispecific antibodies have been approved for various blood cancers, and this class of drugs is rapidly evolving.

What Comes Next: Surveillance and Ongoing Research

The approval of sub-Q mosunetuzumab marks an important step forward in the treatment of R/R follicular lymphoma. However, ongoing surveillance is crucial to monitor long-term outcomes and identify any rare or unexpected side effects. Researchers will continue to explore the optimal use of mosunetuzumab, including its potential in combination with other therapies and in earlier lines of treatment. Further clinical trials are needed to determine whether the benefits observed in the current studies translate to broader patient populations and to refine treatment strategies for this challenging disease. Clinicians will also be closely monitoring real-world data to assess the impact of the sub-Q formulation on patient convenience, treatment adherence, and overall healthcare costs.